Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetylcholine receptor subunit acr-23 (ACR-23), also known as Monepantel-sensitive receptor 1 (MPTL-1), is a critical component of a nematode-specific nicotinic acetylcholine receptor (nAChR) (Kaminsky et al., 2008, Nature). It belongs to the DEG-3 subfamily of ligand-gated ion channels, which are phylogenetically distinct from the nAChRs found in vertebrate hosts (Rufener et al., 2009, Molecular and Biochemical Parasitology). This receptor is primarily expressed in the nervous system and muscles of nematodes, where it facilitates neuromuscular transmission and coordinates locomotion (UniProt P49158). ACR-23 is the definitive molecular target for the amino-acetonitrile derivative (AAD) class of anthelmintics, specifically monepantel (Baur et al., 2015, PLOS Pathogens). When monepantel binds to the receptor, it acts as a potent agonist, causing the channel to remain open and leading to an exhaustive influx of cations (Rufener et al., 2010, PLoS Neglected Tropical Diseases). This overstimulation results in rapid muscle hypercontraction, spastic paralysis, and the eventual death of the parasite. Because the DEG-3 subfamily is absent in mammals, ACR-23 provides a high margin of safety and selectivity for treating helminth infections in livestock (Lecová et al., 2014, Parasitology Research). However, the emergence of resistance, often characterized by loss-of-function mutations or deletions in the acr-23 gene, remains a significant challenge in veterinary medicine.
Agonist of the nematode-specific DEG-3 subfamily nicotinic acetylcholine receptor, causing persistent channel opening, depolarization, and spastic paralysis (Kaminsky et al., 2008).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetylcholine receptor subunit acr-23 (ACR-23) (ACR-23).